Advertisement

Acta Neuropathologica

, Volume 95, Issue 3, pp 287–290 | Cite as

Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines

  • Nuzhat Husain
  • E. A. Chiocca
  • Nikolai Rainov
  • David N. Louis
  • Nicholas T. Zervas
Regular Paper

Abstract

Fas ligand (FasL) is involved in tumor evasion from the immune system. We analyzed 22 human gliomas for expression of FasL and its receptor, Fas. Positive FasL and Fas immunoreactivity was detected in 13 out of 22 tumors by Western blotting and in 15 out of 22 tumors by immunohistochemistry. Immunohistochemistry also showed that Fas and FasL expression was confined to tumor cells. Co-expression of these molecules was confirmed by Western blotting and immunohistochemistry in 4 of 7 glioma cell lines. Co-expression of FasL and Fas within tumor cells suggests that their contribution in vivo to the process of immune system evasion and tumor cell apoptosis is complex and probably involves additional factors.

Keywords

Tumor Cell Western Blotting Immune System Cell Apoptosis Glioma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Nuzhat Husain
    • 1
  • E. A. Chiocca
    • 1
  • Nikolai Rainov
    • 2
  • David N. Louis
    • 1
  • Nicholas T. Zervas
    • 1
  1. 1.Molecular Neuro-oncology Laboratories, Neurosurgery Service, Massachusetts General Hospital-East, 13th Street, Charlestown, MA 02129, USA Tel.: 1-617-726-4684; Fax: 1-617-726-5079; e-mail: Chiocca@helix.MGH. Harvard. EduUS
  2. 2.Department of Neurosurgery, Faculty of Medicine, Martin-Luther-University, Halle, GermanyDE

Personalised recommendations